The 9th ISCC

December 2-3, 2004
Keidanren Hall

December 2, 2004 (Thursday)

13:00 - 13:10

Haruo Sugano (Cancer Chemotherapy Center, Tokyo)

Welcome and Introduction

Kinase Inhibition (Part I)

Chairpersons: Edward A. Sausville (Univ..Maryland, USA)
Ryuzo Ueda (Nagoya City Univ., Nagoya)

13:10 - 13:40

Yoshimasa Uehara (National Institute of Infectious Diseases)

Targeting kinase in the discovery of anticancer drugs

13:40 - 14:10

Edward A. Sausville (Univ. Maryland, USA)

Adaphostin : A new tyrphostin for cancer treatment

14:10 - 14:30

Yoshinori Ito (Cancer Chemotherapy Center, Tokyo)

Lapatinib (GW572016), dual inhibitor of ErbB1 and ErbB2 receptor tyrosine kinases

14:30 - 14:50

Takayasu Kurata (Kinki Univ. Osaka)

EGFR-targeted therapy: EKB 569

14:50 - 15:10

Coffee Break

Kinase Inhibition (Part II)

Chairpersons: Robert H. Shoemaker (NCI-Frederick, USA)
Saburo Sone (Univ. Tokushima, Tokushima)

15:10 - 15:30

Atsushi Ohtsu (National Cancer Center Hospital East, Kashiwa)

EGFR targeted therapy: EMD72000

15:30 - 16:00

Jaap Verweij (Erasmus Univ. Medical Center, Netherlands)

Do we need multitargeted agents or selected agents?

16:00 - 16:20

Discussion

Drug Resistance

Chairpersons: Jaap Verweij (Erasmus University Medical Center, Netherlands)
Yoshiro Niitsu (Sapporo Medical Univ., Sapporo)

16:20 - 16:50

Takashi Tsuruo (Univ. Tokyo, Toyo) and Toshiaki Saeki (National Shikoku Cancer Center, Matsuyama)

MS-209 as a potentiating drug for CAF-therapy against breast cancer

16:50 - 17:20

Stanley B. Kaye (The Royal Marsden Hospital, U.K.)

The role of novel agents in reversing drug resistance

17:20 - 17:30

Discussion

17:30 - 18:30

Mixer

December 3, 2004 (Friday)

Angiogenesis and Metastasis

Chairpersons: Bruce A. Chabner (MGH Cancer Center, USA)
Nagahiro Saijo (National Cancer Center Hospital, Tokyo)

10:00 - 10:30

Michihiko Kuwano (Kurume Univ, Kurume)

Targeting angiogenesis as a inflammatory response in tumor growth, invasion and metastasis

10:30 - 11:00

Jean Pierre Armand (Institut Gustave-Roussy, France)

The antiangiogenic competition in renal cell cancer

11:00 - 11:20

Coffee Break

11:20 - 11:50

Robert D. Mass (Director, Clinical Oncology, Genentech, USA)

Targeting VEGF in human cancer: an update on avastin

11:50 - 12:20

Robert H. Shoemaker (NCI-Frederick, USA)

Targeting β-catenin signaling for anti-metastatic therapeutics

12:20 - 12:30

Discussion

12:30 - 13:30

Lunch Break

New Drugs under Clinical Consideration

Chairpersons: Jean-Pierre Armand (Institut Gustave Roussy, France)
Masahiro Fukuoka (Kinki Univ., Osaka)

13:30 - 13:50

Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

PS341

13:50 - 14:10

Yukito Ichinose (National Kyushu Cancer Center, Fukuoka)

Chemotherapy trials using (S-1) DPD-inhibitory fluoropyrimidine for advanced non-small cell lung cancer patients in Japan

14:10 - 14:30

Yasuhide Yamada (National Cancer Center Hospital, Tokyo)

Phase I and pharmacokinetic/pharmacogenomic study of E7070

14:30 - 15:00

Tomomitsu Hotta (Tokai Univ, Isehara)

Erythropoietin in cancer chemotherapy

15:00 - 15:10

Discussion

15:10 - 15:30

Coffee Break

Molecular Target Therapy of Cancer: Future Prospective

Chairpersons: Stanley B. Kaye (the Royal Marsden Hospital, U.K.)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)

15:30 - 16:00

Masaaki Matsuura (Cancer Institute, Tokyo)

Pharmacogenomics studies in cancer patients for genomic prediction of adverse effect

16:00 - 16:30

Bruce A. Chabner (MGH Cancer Center, USA)

Targeted Drug Development: Impact of Selective Factors

16:30 - 17:00

Enrico Mihich (Grace Cancer Drug Center, Roswell Park Cancer Institute, USA)

Development of new anticancer treatment

17:00 - 17:20

Discussion

17:20 - 17:30

Takashi Tsuruo (Univ. Tokyo, Tokyo)

Closing Remark

Page TOP